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ABSTRACT
Muscle injuries among athletes require a complete recovery to be able to function optimally as before. 
However, in spite of implementing the management with PRICE (Protection, Rest, Immobilization, 
Compression and Elevation), during the recovery processes, fibrotic tissue will be formed, which 
is an unwanted non-functional muscle. Losartan is a blood pressure-lowering drug which has the 
inhibitory effect of  inhibitory effect of TGF-β cytokines (fibrotic tissue regulators). TGF-β is the key 
to fibrotic formation and differentiation. Losartan has an effect on decreasing the TGF-β production 
and it may affect the fibrotic tissue. This research is conducted by an experimental comparative method 
on the rabbit as study objects. Based on Federer formula sampling, twenty samples totally occurred. 
The random sampling method is adopted for comparing fibrotic tissue in two different groups (control 
group and losartan group). Losartan is administered orally. There were significant differences in the 
proportion of fibrotic tissue between the sample groups. The losartan group showed that the level 
of fibrotic intensity, distribution, and H-score was decreased compared to the control group. 
Moreover, the result of Mann Whitney statistic test, for determining the H-score for both groups, 
showed that p is less than 0.05 (p<0.05), which implies that this research is statistically significant. 
This research proves that giving Losartan tablets brings a significant impact in reducing the 
formation of muscle fibrosis in muscle injury grade 1 in gastrocnemius rabbits.
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INTRODUCTION
Muscle injury grade 1 is a common injury which placed 
up to 90% among all of the muscle injury (Medicine, 
2012). The standard treatment for this injury is PRICE 
(Protect, Rest, Ice, Compression, Elevation), yet 
the healing process produces fibrotic tissues, which 
increases the possibility of recurrences as the muscle 
becomes weaker and less flexible (Nugroho, 2016). 
In the last decade, the incidence of muscle injuries is 
increasing. Muscle injuries divided into two based on 
the mechanism, indirect and direct types. Direct type 
is if there no direct external trauma appear (Ekstrand, 
Askling, Magnusson, & Mithoefer, 2013).  There are 
either structural injuries due to longitudinal distraction 
that make tears the muscle tissue or without evidence of 
a tear (Ekstrand et al., 2013). The most common direct 
case is because compressive to the thigh that usually 
compresses the muscles structures. Different from 
indirect type, muscle fibers usually are not torn. Direct 
injuries, especially muscle contusion, are common in 
sports, usually in high body contact sports types, such 
as football, rugby, basketball, and others. This kind of 
injury makes pain and may interfere joint motion of 
the athletes after the healing process (Trojian, 2013). 
Fibrotic tissue usually occurred after muscle injuries, 
substitute the functional muscle fiber to suboptimal 
muscle function. It makes muscles group less flexible 
and high risk to recurrence, in some case makes chronic 
pain. Therefore, we develop the new treatment in the 
management of muscle injury use Losartan drugs, this is 
a pilot study to applied Losartan in athlete muscle injury.
Losartan is anti-hypertension drugs that widely known 
as angiotensin II receptor blocker (ARB) type, effective 
to decrease blood pressure with minimum complication 
and can be used in all age groups.  Also, effective to 
treat cardiomyopathy and chronic renal disease. These 
drugs causing directly vasodilation of periphery blood 
vessel, and by reducing secreting of aldosterone and 
vasopressin. Activation of receptor angiotensin II by 
angiotensin II make production of thrombospondin-I, 
this secreted glycoprotein have been shown to be the 
regulator of TGF-β activation. Therefore, inhibition of 
ATII and subsequences decreasing of TSP-1 will block 
the TGF-β activation (Cohn et al., 2007).
Recent research shows the effectiveness of blocking 
TGF-β production for fibrotic problems using anti-
fibrotic agents, such as Decorin, Relaxin, and Suramin 
have good results (Mann et al., 2011; Terada et al., 
2013). In Indonesia, this kind of drugs is difficult to 
find, have an expensive price (0,5 – 2 USD/tablet) and 
have a lot of complication (Yang et al., 2011). Other 
research showed that Losartan also possesses the capacity 
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of decreasing the TGF-β secretion over mice which 
have Duchenne Muscular Dystrophy (DMD) (Meinen 
et al., 2012; Pessina et al., 2014).  TGF-β is cytokine 
key to differentiate myoblast to become myofibroblast, 
decreasing this cytokine will increase myocyte 
(functional muscle cell) production.
METHODS
This research was conducted using the experimental 
comparative method on the animal as study objects. The 
random sampling method was adopted for comparing 
quality and quantity value of the formation of fibrotic 
tissue in two different groups with muscle injury grade I 
based on histologic sampling and calculate with H-score. 
The experiment was conducted in the Laboratory of 
Medical Research Unit of our institution from April to 
May 2016.
For this experiment, the subjects were rabbits which met 
the inclusion criteria: adult male rabbit, New Zealand 
races, 7 months old, weight 1-1,5 kg. Drop out criteria 
were decided as infection, fracture, dead rabbit, and 
changes in animal behavior. Using Federer formula to 
specify the number of samples needed, it was found 
that the experiment was totally to have 20 rabbits. Each 
group have 10 samples of rabbit.
To begin with, the muscle trauma was created on 
each rabbit by employing a dropping mass technique, 
which utilizing 1 kg load that was dropped from 0,5 
meter high on the rabbits’ gastrocnemius muscle, then 
bandaged using circular casts. Shortly afterwards, the 
research subjects were divided into two groups, the first 
group is the control group and the second group is the 
losartan treatment rabbits group. Group 1 as a control 
group was not administered losartan, while group 2 as 
treatment group was administered with losartan 25 mg/
KgBW using the small orogastric tube.
The research procedure included preparations of 
muscle injury using drop mass technique, circular cast, 
inserting losartan (25 mg/KgBW) for three weeks, then 
harvest of the gastrocnemius muscle, and histopathology 
Hematoxylin-Eosin and Van Goisson Staining Protocol 
Goisson examination were done in the Department of 
Pathology Anatomy. Then, the evaluation of fibrotic 
intensity and distribution was done by an anatomical 
pathologist.
Histopathology measurement was done using the Histo-
score system. This score is divided into 2 subjects, fibrotic 
intensity and fibrotic distribution. The range of fibrotic 
scoring is 0-3, score 0 if there are no fibrotic tissue (Figure 
1), score 1 if the fibrotic intensity is weak, score 2 for 
moderate fibrotic intensity (Figure 2), and score 3 for strong 
moderate intensity (Figure 3), while fibrotic distribution 
was divided into 4 groups, with range 1-4. Score 1 Figure 1. Muscles without fibrotic area
Figure 2. Muscles with moderate fibrotic intensity
Figure 3. Muscles with strong fibrotic intensity
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Sample No F i b ro t i c Intensity
Fibrotic 
Distribution H-Score
Group I 1 3 2 8
2 3 1 4
3 2 2 6
4 2 2 6
5 3 2 8
6 3 1 4
7 2 2 6
8 3 1 4
9 2 1 3
10 2 2 6
Mean 5.5
Table 1. Fibrotic intensity, fibrotic distribution, and 
H-Score in control group
if the fibrotic distribution is less than 20%, score 2 
if the fibrotic distribution within 20-50%, score 3 if 
the fibrotic distribution is 51-80%, and score 4 if the 
fibrotic distribution more than 80% (Gal et al., 2008).
Later, the results of the special staining of the two groups 
were compared using the scoring of the H-score system :
H-Score = (Fibrotic Instensity+1) x Fibrotic 
Distribution. 
This score has a range from 2 to 16. Afterwards, the data 
collection and statistical analysis were carried out by 
using Kolmogorov-Smirnov and Mann-Whitney tests 
with p<0.05 for significant differences.
Table 2. Fibrotic intensity, fibrotic distribution, and 
H-Score in Losartan treatment group
Sample No Fibrotic 
Intensity
Fibrotic 
Distribution
H-Score
Group 2 1 3 1 4
2 3 1 4
3 3 1 4
4 0 0 0
5 0 0 0
6 0 0 0
7 0 0 0
8 0 0 0
9 0 0 0
10 0 0 0
Mean 1.2
RESULTS
Table 1 and 2 showed the results of this study. There 
was decreasing mean of fibrotic tissue formation in 
muscle healing after blunt trauma, the mean control 
group is 5,5 and mean for treatment group is 1,2. 
Table 3 below explained the overall characteristic of all 
fibrotic intensity, fibrotic distribution, and H-score in 
both groups. From the experiment, it was found that 
5 samples (25.0%) showed moderate intensity, 8 
samples (40.0%) indicated strong fibrotic intensity, and 
7 samples (35.0%) did not have fibrotic. The mean for 
H-Score was 3.3500±2.833.
The data was analyzed using Kolmogorov-Smirnov 
statistical test (Table 4). The result was p = 0.015 
(significant if p<0.05). It shows that there were 
meaningful differences in the proportion of fibrotic 
intensity and fibrotic distribution variable.
Meanwhile, Mann-Whitney analysis was used to 
calculate the distribution of H-score, as the data was 
abnormal. From the formula, as seen in Table 5, it 
resulted that fibrotic H-score was p = 0.0001 (significant 
if p<0.05). This, therefore, concluded that there were 
significant differences in the mean between 2 sample 
groups.
Table 3. Characteristic of result sample group (control 
and Losartan treatment group)
Variable N=  20
Fibrotic Intensity
Mild 0 (0,0%)
Moderate 5 (25.0%)
Strong 8 (40.0%)
None 7 (35.0%)
Fibrotic Distribution
0 7 (35.0%)
<20% 7 (35.0%)
20-50% 6 (30.0%)
51-80% 0 (0,0%)
>80% 0 (0,0%)
H-Score Fibrotic
Mean±STD 3.3500±2.833
Median 4.000
Range (min-max) 0.00-8.00
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Table 5. Mann Whitney H-Score Result
Variable
Group
P ValueGroup 1 Group 2
N= 10 N= 10
H-Score Fibrosis 0.0001**
Mean±STD 5.500±1.7159 1.200±1.932
Median 6.000 0.000
Range (min-max) 3.00-8.00 0.00-4.00
Group 1: Control Group; Group 2: Losartan Treatment Group
Significant value if p<0.05. Marker** showed p-value <0.05, 
concluded significant or meaningful in the statistic
DISCUSSION
Investigation anti-fibrotic properties of angiotensin 
receptor type I blocker (ARB) in muscle healing from 
previous studies showing effects on myocardial and 
smooth muscle tissue injury. The role of angiotensin 
II in muscle fibrotic after injury is well documented in 
the cardiac literature, where angiotensin II antagonists 
with ARBs are noted to significantly improve cardiac 
contractility and cardiac output (Gremmler et al., 
2000). The histologic analysis also suggests that 
heart repair mechanisms are associated with decreased 
fibrosis and enhanced regeneration. The effects of ARB 
on skeletal muscle healing, however, remain largely 
unstudied.
The fibrotic formation is the main problem to be solved in 
the muscle healing process, with the main intention is to 
maximize muscle’s functional healing. This suboptimal 
healing makes muscles weaker and less flexible, and it 
also increases the chance of re-rupture. As we know, TGF-β 
cytokines is a regulator for fibrotic tissue production, 
which transform myoblast into myofibroblast, which 
is then differentiated to become fibrotic tissue in chronic 
muscle pathology (Meinen et al., 2012). Although TGF-β 
blocking substances have already been found and known 
for its effectiveness in fibrotic tissue problems, such as 
Decorin, Suramin, and Relaxin (Mann et al., 2011; Terada 
et al., 2013), yet these drugs are not yet openly distributed 
in Indonesia, which makes it quite expensive and mostly 
requires injection use. Losartan is thus chosen for its ability 
to decrease TGF-β cytokine and its well-availability in all 
age group (Cohn et al., 2007). We hypothesized, that 
Losartan would improve the muscle healing process in 
acute muscle injury by decreasing fibrotic tissue.
Losartan tablet is an ARB drug which is commonly used 
for hypertension. Receptor angiotensin Type 1 regulates 
Thrombospondin (TSP 1) where the TSP 1 is the controller 
of TGF-β production. Losartan inhibits the activity of 
Table 4. Kolmogorov Smirnov result
Variable
Group
P ValueGroup 1 Group 2
N= 10 N= 10
Fibrotic Intensity 0.015**
Mild 0 (0.0%) 0 (0.0%)
Moderate 5 (50.0%) 0 (0.0%)
Strong 5 (50.0%) 3 (30.0%)
None 0 (0.0%) 7 (70.0%)
Fibrotic Distribution 0.015**
0 0 (0.0%) 7 (70.0%)
<20% 4 (40.0%) 3 (30.0%)
20-50% 6 (60.0%) 0 (0.0%)
51-80% 0 (0.0%) 0 (0.0%)
>80% 0 (0.0%) 0 (0.0%)
Group 1: Control Group; Group 2: Losartan Treatment Group
Significant value if p<0.05. Marker** showed p-value <0.05, 
concluded significant differences in proportion.
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Figure 4. Losartan effect to the acute muscles injury
angiotensin, thus decrease the TGF-β cytokines production 
then decreasing of fibrotic tissue formation (Figure 4). 
The measurement of the fibrotic intensity and fibrotic 
distribution, obtained in the experiment, were done by 
anatomy pathologist before converted to the H-score.
The statistic result for H-score was p = 0.0001 (significant 
if p < 0.05), which showed that there was a significant 
difference between the H-Score of the control group and 
the H-score of the administered group. As a finding of this 
research (see table 4), Losartan tablets gives significant 
influence in the fibrotic formation on acute muscle injury 
grade 1. It is similar to Meinen research which had a 
conclusion that Losartan could decrease fibrotic tissue but 
in chronic muscle pathology (Meinen et al., 2012).
This finding may clinically fascinate anti-fibrotic therapy 
and potentially developed so far for healthy individuals 
with an acute skeletal muscle injury. 
Clinical trials on losartan as an anti-fibrotic agent 
to promote optimal muscle healing is not yet clear, 
therefore it is important to pay attention to its potential 
disadvantages effects of angiotensin II receptor 
antagonist. The adverse effect profile of ARB is very 
minimal compared to other antihypertensive drugs; 
dose-related side effects are hypotension, whereas 
non-dose related adverse include headaches, dizziness, 
weakness, and fatigue (Aronson, 2015).
CONCLUSION
In summary, we have demonstrated in rabbits model 
that losartan treatment regimen can improve overall 
skeletal muscle healing after a muscle contusion injury 
by inhibiting the development of fibrosis. Losartan 
treatment accelerated the functional recovery of the 
muscle after injury and, more importantly, this treatment 
could be readily applied clinically. 
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